Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder
- PMID: 18253146
- DOI: 10.1038/sj.clpt.6100491
Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder
Abstract
To describe the pregabalin exposure-adverse event (AE) (dizziness) relationship in patients with generalized anxiety disorder, separate models were developed for the incidence of AE and for the conditional severity of AE, given that an AE has occurred using patient data from six clinical studies. The incidence component was modeled using a nonlinear logistic regression model. The conditional severity component was modeled as an ordered categorical variable with a proportional odds model to capture the severity on any given day. A Markov element was introduced to account for the correlation between neighboring observations. The proportional odds model including a time course of appearance and disappearance of AE could adequately describe the time course of probability of dizziness. Incorporating a transition model including Markov elements improved the model fit and greatly improved the predictability of the time course of probability of dizziness.
Similar articles
-
Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder.J Clin Pharmacol. 2011 May;51(5):706-18. doi: 10.1177/0091270010370973. Epub 2010 Jul 27. J Clin Pharmacol. 2011. PMID: 20663989
-
Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder.J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):565-84. doi: 10.1007/s10928-009-9137-5. Epub 2009 Nov 8. J Pharmacokinet Pharmacodyn. 2009. PMID: 19904583
-
Pregabalin for the treatment of generalized anxiety disorder.Ann Pharmacother. 2012 Mar;46(3):424-9. doi: 10.1345/aph.1Q405. Epub 2012 Mar 6. Ann Pharmacother. 2012. PMID: 22395254 Review.
-
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.Arch Gen Psychiatry. 2005 Sep;62(9):1022-30. doi: 10.1001/archpsyc.62.9.1022. Arch Gen Psychiatry. 2005. PMID: 16143734 Clinical Trial.
-
Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.Expert Rev Neurother. 2007 Jul;7(7):769-81. doi: 10.1586/14737175.7.7.769. Expert Rev Neurother. 2007. PMID: 17610384 Review.
Cited by
-
Assessment of Demographic and Socio-Behavioral Factors on Adherence to HIV Pre-Exposure Prophylaxis Using a Markov Modeling Approach.Front Pharmacol. 2019 Jul 12;10:785. doi: 10.3389/fphar.2019.00785. eCollection 2019. Front Pharmacol. 2019. PMID: 31354496 Free PMC article.
-
Modelling overdispersion and Markovian features in count data.J Pharmacokinet Pharmacodyn. 2009 Oct;36(5):461-77. doi: 10.1007/s10928-009-9131-y. Epub 2009 Oct 2. J Pharmacokinet Pharmacodyn. 2009. PMID: 19798550 Clinical Trial.
-
The use of clinical utility assessments in early clinical development.AAPS J. 2009 Mar;11(1):33-8. doi: 10.1208/s12248-008-9074-z. Epub 2009 Jan 16. AAPS J. 2009. PMID: 19145490 Free PMC article. Review.
-
Pharmacodynamic models for discrete data.Clin Pharmacokinet. 2012 Dec;51(12):767-86. doi: 10.1007/s40262-012-0014-9. Clin Pharmacokinet. 2012. PMID: 23179578 Review.
-
Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):96-105. doi: 10.1002/psp4.12487. Epub 2020 Jan 30. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 31877239 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical